Recent News

• 09.15.2025 - Spruce Biosciences Resumes Trading on the Nasdaq Capital Market
• 08.14.2025 - Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
• 08.14.2025 - Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B (MPS IIIB)
• 07.24.2025 - Spruce Biosciences Announces Reverse Stock Split
• 06.12.2025 - Spruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market

Recent Filings

• 08.14.2025 - 8-K Current report
• 08.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.14.2025 - EX-99.1 EX-99.1
• 08.13.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.13.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 07.24.2025 - 8-K Current report
• 07.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.24.2025 - 4 Statement of changes in beneficial ownership of securities